TP53 and prostate cancer: Mutation frequencies for TP53 are extremely variable in prostate cancer studies (ranging from 3–45%), but overall it is consensual that most clinically confined tumors have no mutations, whereas metastatic and androgen independent cancers harbor a high frequency of TP53 mutations [20,21].